1 – 44 of 44
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Fluid Biomarker Changes After Amyloid-β–Targeting Drugs
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Digital remote assessment of speech acoustics in cognitively unimpaired adults : feasibility, reliability and associations with amyloid pathology
(
- Contribution to journal › Article
-
Mark
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Novel avenues of tau research
(
- Contribution to journal › Scientific review
- 2023
-
Mark
Severe CTE and TDP-43 pathology in a former professional soccer player with dementia : a clinicopathological case report and review of the literature
(
- Contribution to journal › Article
-
Mark
A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
(
- Contribution to journal › Article
-
Mark
Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis
(
- Contribution to journal › Article
- 2022
-
Mark
Blood-based biomarkers for Alzheimer's disease : towards clinical implementation
(
- Contribution to journal › Scientific review
-
Mark
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
Rationale and design of the “NEurodegeneration : Traumatic brain injury as Origin of the Neuropathology (NEwTON)” study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy
(
- Contribution to journal › Article
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
The natural history of primary progressive aphasia : beyond aphasia
(
- Contribution to journal › Article
-
Mark
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers : Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
(
- Contribution to journal › Article
- 2021
-
Mark
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
(
- Contribution to journal › Article
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study
(
- Contribution to journal › Article
- 2020
-
Mark
Amyloid-β PET and CSF in an autopsy-confirmed cohort
(
- Contribution to journal › Article
-
Mark
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
(
- Contribution to journal › Article
-
Mark
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19
(
- Contribution to journal › Letter
-
Mark
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
(
- Contribution to journal › Article
-
Mark
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
(
- Contribution to journal › Article
-
Mark
CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
(
- Contribution to journal › Article
- 2019
-
Mark
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
(
- Contribution to journal › Article
-
Mark
Applying the ATN scheme in a memory clinic population : The ABIDE project
(
- Contribution to journal › Article
-
Mark
Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment : the effect of age at onset
(
- Contribution to journal › Article
-
Mark
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE) : a modelling study
(
- Contribution to journal › Article
-
Mark
Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia
(
- Contribution to journal › Article
- 2018
-
Mark
Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
(
- Contribution to journal › Article
- 2017
-
Mark
Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
(
- Contribution to journal › Article
-
Mark
Consensus guidelines for lumbar puncture in patients with neurological diseases
(
- Contribution to journal › Article
- 2016
-
Mark
Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of lewy body diseases : Results from a large multicenter cohort
(
- Contribution to journal › Article
-
Mark
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
(
- Contribution to journal › Article
- 2015
-
Mark
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
(
- Contribution to journal › Article
-
Mark
Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.
2015) In Alzheimer's & Dementia(
- Contribution to journal › Article
-
Mark
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
(
- Contribution to journal › Article
- 2014
-
Mark
The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?
(
- Contribution to journal › Article
- 2012
-
Mark
Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
2012) In Neurology(
- Contribution to journal › Article